Clinical trials: Neuroendocrine Tumor Metastatic
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Malignant Neoplasm
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with…
- Trial name
- NCT06894771
- Testing
- MK-4700, Pembrolizumab
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Melanoma
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
This was a retrospective cohort study using the MarketScan health care administrative claim databases: Truven Health Analytics' MarketScan Commercial Claims and Encounters; MarketScan Medicare Supplement and Coordination of…
- Trial name
- NCT05848219
- Where
- United States
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Melanoma
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
This is a two-arm, open-label, randomized Phase III study comparing single agent GSK1120212 to chemotherapy (either dacarbazine or paclitaxel) in subjects with Stage IIIc or Stage IV malignant cutaneous melanoma.
- Trial name
- NCT01245062
- Testing
- GSK1120212, Chemotherapy
- Where
- 112 sites in United States, Argentina and 17 more
- Volunteers
- 322 people
- Sponsor
- GlaxoSmithKline
Melanoma
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
This study will be conducted with the aim of estimating the effectiveness, safety, patterns of use of nivolumab, and characteristics of patients with unresectable or metastatic melanoma, treated with nivolumab monotherapy in the…
- Trial name
- NCT03504696
- Testing
- Non-interventional
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
This study will assess the preliminary anti-tumor activity and safety profile of a combination of bevacizumab and dacarbazine in participants with unresectable/metastatic melanoma not previously treated with chemotherapy for…
- Trial name
- NCT01164007
- Testing
- Bevacizumab, Dacarbazine
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
The objective of this study is to assess the efficacy and safety of TLN-232 used to treat patients with metastatic melanoma that recur/progress after receiving first line systemic therapy.
- Trial name
- NCT00735332
- Testing
- TLN-232
- Where
- 4 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- Thallion Pharmaceuticals
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Liver Neoplasms
TheraSphere Japan Pre-Market Study
To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.
- Trial name
- INDIGO (NCT07377487)
- Testing
- TheraSphere Y-90 glass microsphere
- Where
- 5 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Boston Scientific Corporation
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
OPALINE : A Study Of Morbidity And Mortality At 2 Years
A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease…
- Trial name
- OPALINE (NCT02264665)
- Testing
- sunitinib, everolimus, chemotherapies recommended in france
- Where
- 35 sites in France
- Volunteers
- 144 people
- Sponsor
- Pfizer
Metastatic Melanoma
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic virus in combination with paclitaxel and carboplatin is effective and safe in the treatment of metastatic melanoma.
- Trial name
- NCT00984464
- Testing
- REOLYSIN, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Oncolytics Biotech
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Gastroenteropancreatic Neuroendocrine Tumors
Community-based Neuroendocrine Tumor (NET) Research Study
The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot.
- Trial name
- NCT02730104
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ipsen
Melanoma
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.
- Trial name
- LOGIC (NCT01820364)
- Testing
- LGX818
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Array BioPharma
Metastatic Melanoma
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
- Trial name
- NCT03445533
- Testing
- Ipilimumab, Tilsotolimod with Ipilimumab
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 481 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Melanoma
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
The study design included an open-label, dose escalation phase followed by a blinded, randomized phase, which combined epacadostat (an oral IDO1 inhibitor) with an approved therapy and compared to approved therapy plus placebo in…
- Trial name
- NCT01604889
- Testing
- Epacadostat, ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Incyte Corporation